COMPARATIVE STUDY BETWEEN CILOSTAZOL AND PENTOXIFYLLINE TO CURE PERIPHERAL ARTERIAL DISEASE
Main Article Content
In the West, diabetes mellitus is the leading cause of end-stage renal disease, and diabetic kidney disease is one of the most serious consequences of the condition. Delaying the onset of this illness requires novel techniques that go beyond the management of conventional risk factors to address the underlying pathogenic processes. Inflammation is now understood to have a pivotal role as an unique pathogenic component in the onset and progression of renal damage in diabetics. For almost 30 years, clinicians have relied on the rheologic features of the nonspecific phosphodiesterase inhibitor pentoxifylline to treat peripheral vascular disease. The effects of cilostazol and pentoxifylline on intermittent claudication in PAD patients: a randomized, double-blind, placebo-controlled trial. The trial was prospective and participants were randomly assigned to one of two groups. Patients in Group I (n=35) were given Tab. Pentoxifylline 400 mg thrice daily, whereas those in Group II (n=35) were given Tab. Cilostazol 100 mg b.i.d. Both the Intermittent Claudication Distance and the Acute Claudication Distance increased greater in the Cilostazole group than in the Pentoxifylline group.